Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer

Jelena M. Meek

doi:10.1016/j.ejca.2026.116984

Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer

2026-08-09

0

OA

AI

J

Jelena M. Meek *

I

Iske F. van Luijk

M

Mark A.J. Gorris

C

Corneel Coens

E

Evgenia Martynova

T

Thomas J. Van Ee

A

Antonio Casado

H

Helena C. van Doorn

I

Ignace Vergote

I

I Jolanda M. de Vries

G

Gemma G. Kenter

P

Petronella B. Ottevanger

DOI：10.1016/j.ejca.2026.116984

Original

Original request for help

Save

Abstract

En 中文

The tumor microenvironment (TME) in cervical cancer may undergo immunological changes during neoadjuvant chemotherapy (NACT). The primary aim of this study was to elucidate changes in the TME of cervical cancer during platinum-containing NACT and to evaluate whether these immunological changes correlated with survival. Characterizing these changes may help identify the optimal timing for future integration of immunotherapy. This study examined alterations in lymphocyte subsets in patients with FIGO 2009 stage IB2–IIA2 cervical cancer treated with cisplatin-based NACT.

Keywords:

Cervical cancer

Tumor microenvironment

Regulatory T-cells

Neoadjuvant chemotherapy

Immunotherapy

Multiplex immunohistochemistry

Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer

Abstract

Journal

Organization